The global DNA Vaccines Market is valued at USD 2.38 Billion in 2020 and is expected to reach USD 10.95 Billion by 2027 with a CAGR of 24.4% over the forecast period.
Global DNA Vaccines Market Global Size, Trends, Competitive, Historical & Forecast Analysis to 2021-2027, Increasing prevalence of Cancer, rising number of COVID-19 cases, and increased use of DNA vaccines in veterinary diseases are major factors anticipated to drive the Global DNA Vaccines Market in the forecast period.
The technique of injecting a specific antigen DNA-coding sequence by which cells directly produce an antigen, resulting in a protective immunological response against disease is known as DNA vaccination. These vaccine codes are for antigen-specific proteins. DNA vaccines are majorly used for veterinary use and there has been promising research using the vaccines for viral, bacterial and parasitic diseases, as well as to several types of tumors. DNA vaccine is also known as a third-generation vaccine. Rabies virus, lymphocytic choriomeningitis virus, malarial parasites and mycoplasmas, Hepatitis B virus, influenza virus, HIV virus are infectious agents used for obtaining genes. The immune response focused on the antigen of interest, DNA vaccines are cost-effective and there is less risk for infection. In DNA vaccines antigen presentation by MHC class I and class II molecules, long-term persistence of immunogen. DNA vaccines are more stable, cost-efficient, easy to manufacture and safe in handling and used therapy for cancer, allergies, autoimmune diseases and infectious disease.
The COVID-19 pandemic has shown positive impact on global DNA vaccines market. The sudden spread corona virus and the increasing number of cases highlight the urgent development of vaccines and also raise the demand of DNA vaccines. In DNA vaccines host cells are temporarily transformed into factories that produce proteins of the SARS-CoV-2 and immune system notices these proteins to develop antibodies that neutralize and prevent the infection. Hence demand of DNA vaccine increasing rapidly. In this way, improvement on DNA antibodies against COVID-19 and clinical preliminaries just as approvals for vaccines positively affected the global DNA vaccines market.
The Global DNA vaccines market is segmented into on the basis of type, technology, application, therapeutic indications and region & country level. On the basis of type, the global DNA vaccines market is segmented into human DNA vaccines, animal DNA vaccines. On the basis of technology, the market is segmented into pDNA vaccines technology and pDNA delivery technology. Based upon application, the global DNA vaccines market is segmented into veterinary diseases, human diseases, allergies and others. On the basis of end users, the market is segmented into human health, animal health, research application. On the basis of therapeutic indications, the global DNA vaccines market is segmented into vector borne disease and cancer.
The regions covered in global DNA vaccines market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global DNA vaccines is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, Southeast Asia, Middle East, GCC (UAE, Egypt, Saudi Arabia), Africa, etc.
25th September 2021; First DNA vaccines against COVID-19, which can be administered to all people above the age of 12 years had announced by Prime Minister Narendra Modi. The vaccine will be given to kids between age group of 12-18 in the country. The vaccine development and manufacturing with limited resources is under India’s The Sewa Paramo Dharma Campaign. The needle free COVID-19 vaccine, ZyCoV-D (Zydus Cadila's indigenously developed) permitted by Drugs Controller General of India beneath Emergency Use Authorisation (EUA).
Increasing prevalence of cancer, rising number of Covid-19 cases, and Growing use of DNA vaccines in veterinary diseases are major factors anticipated to drive the Global DNA Vaccines Market
One of the major factors driving the growth of the global DNA vaccines market is increasing prevalence of cancer. Cancer has been a one of the major causes of death worldwide. DNA vaccines are used in cancer immunotherapy that treats cancer by strengthening the body’s natural defences against the cancer. DNA vaccines are used in cancer treatment by using generic cells which are a type of immune cell. Dendritic cell vaccines stimulate immune system to respond to an antigen on tumour cells. The generic cell vaccine Sipuleucel-T vaccine was approved FDA for treatment of men having advanced prostate cancer. Thus, use of DNA vaccine for the treatment of cancer boosting the market growth. For instance, according to WHO (World Health Organization), in 2020, about 10 million peoples dead by cancer.
In addition to that, another factor driving the growth of DNA vaccines is the raising of the number of COVID-19 cases. In DNA vaccines host cells are momentarily transformed into factories that create proteins of the SARS-CoV-2 and the immune system observes these proteins to grow antibodies that neutralize and avoid the infection. DNA vaccines have much more benefits than traditional vaccines like strong cellular immune response, higher safety margin, a simple production process as per cGMP norms, lack of any infectious agent, and a vigorous platform for large-scale production. Hence, use of these vaccines for COVID-19 is expected to accelerate market growth. For example, as per the news published on 11th August 2020, “Sputnik V” based on viral vector technology against COVID-19 was approved by Russia and was the first country to approve.
Furthermore, growing use of DNA vaccines in veterinary diseases also drives the global DNA vaccines market. DNA vaccines are most promising method of vaccination for animals. A plasmid encoded antigen encoding an antigen of the pathogen. The gene of interest is inserted into a plasmid, along with appropriate genetic elements and particular gene is expressed against antigen and immunity is developed in animals. For instance, In May 2017, the launch of first DNA vaccines designed for animals by AgriLabs. This vaccine has ENABL adjuvant technology and require low- dose substitute for the animal health industry. This vaccine is suitable for avian influenza. These technological DNA vaccines fueling the growth of DNA vaccines in the forecast period. However, the limitations of DNA vaccines to only protein immunogens are restraining the DNA vaccines market growth. In spite of that, large scale manufacturing compared to conventional vaccines and research & development are providing opportunities in the global DNA vaccines market.
North America Dominates the Global DNA Vaccines Market
North America dominates the global DNA vaccines market due to the increasing number of cancer patients, research & development in DNA vaccines,s and the presence of key players in this region. DNA vaccines are used for treating cancer. Thus, the adoption of DNA vaccines is fueling the growth of the market in this region. For example, according to the National Institute of Cancer, in 2020, about 1,806,590 new cases of cancer are diagnosed in the United States. In addition to that, research and development for the covid virus further accelerate the market growth. For instance, as per the news published on 9th November 2021, U.S FDA permitted phase 3 division for COVID-19 DNA vaccine to INOVIO. Moreover, the presence of key players and government investments along with increased awareness for vaccines which are constantly creating technological advancement followed by the launch of new vaccines are expected to drive the market growth.
Asia-Pacific is anticipated to be the fastest-growing regional market over the forecast period due to the increasing population and rising number of COVID-19 patients and government initiatives for research. An increasing number of COVID patients in India boosted the market growth of the global DNA vaccine in the Asia-Pacific region. For instance, according to the World Health Organization (WHO), as of 14th December 2021, there are 34,703,644 confirmed cases of COVID-19, in India. In addition to that research by key players for the development of vaccines is augmenting the market growth. For instance, Indian pharmaceutical company Zydus Cadila developed the COVID-19 DNA, it was the first DNA vaccine that received approval, and this vaccine approval represents a noteworthy step forward for DNA vaccines. Moreover, government initiatives and investment for instance, according to IBEF (Indian Brand Equity Foundation) in October 2021, US$ 100 million planned to invest by Biz2Credit, a fintech company, in India for the next five years on research and development activities and expansions. Thus, these investments are expected to drive market growth in the Asia Pacific region.
Middle East and Africa
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 2.38 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 10.95 Billion|
|Tables, Charts & Figures:||175|
|DNA Vaccines Companies||Novartis Ag, Pfizer Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., Merck & Co., Gilead Sciences Inc., Sanofi-Aventis, Johnson & Johnson, others|
|Segments Covered||By Type, By Application, By Technology, By Application|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
Kemp House, 152 - 160 City Road, London EC1V 2NX
© Copyright 2022-23 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®